Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Lutrick, Karen ; Rivers, Patrick ; Yoo, Young M. ; Grant, Lauren ; Hollister, James ; Jovel, Krystal ; Khan, Sana ; Lowe, Ashley ; Baccam, Zoe ; Hanson, Hanna ; Olsho, Lauren E.W. ; Fowlkes, Ashley ; Caban-Martinez, Alberto J. ; Porter, Cynthia ; Yoon, Sarang ; Meece, Jennifer ; Gaglani, Manjusha ; Burns, Joy ; Mayo Lamberte, Julie ; Nakayima Miiro, Flavia ; Bissonnette, Adam ; LeClair, Lindsay ; Kutty, Preeta K. ; Romine, James K. ; Stefanski, Elisha ; Edwards, Laura J. ; Ellingson, Katherine ; Gerald, Joe K. ; Bedrick, Edward J. ; Madhivanan, Purnima ; Krupp, Karl ; Gerald, Lynn B. ; Thompson, Mark ; Burgess, Jefferey L.
• Description:
  The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine has demonstrated high efficacy in preventing infection with SARS-CoV-2 (the Virus that causes COVID-19) in randomized placebo-controlled Phase III trials in persons aged 12-17 years (referred to as adolescents in this report) (1); however, data on real-word vaccine effectiveness (VE) among adolescents are limited (1-3). As of December 2021, the Pfizer-BioNTech vaccine is approved by the Food and Drug Administration (FDA) for adolescents aged 16-17 years and under FDA emergency use authorization for those aged 12-15 years. In a prospective cohort in Arizona, 243 adolescents aged 12-17 years were tested for SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) each week, irrespective of symptoms, and upon onset of COVID-19-like illness during July 25-December 4, 2021; the SARS-CoV-2 B.1.617.2 (Delta) Variants was the predominant strain during this study period. During the study, 190 adolescents contributed fully vaccinated person-time (≥14 days after receiving 2 doses of Pfizer-BioNTech vaccine), 30 contributed partially vaccinated person-time (receipt of 1 dose or receipt of 2 doses but with the second dose completed <14 days earlier), and 66 contributed unvaccinated person-time. Using the Cox proportional-hazards model, the estimated VE of full Pfizer-BioNTech vaccination for preventing SARS-CoV-2 infection was 92% (95% CI = 79%-97%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local Virus circulation. These findings from a real-world setting indicate that 2 doses of Pfizer-BioNTech vaccine are highly effective in preventing SARS-CoV-2 infection among Arizona adolescents. CDC recommends COVID-19 vaccination for all eligible persons in the U.S. including persons aged 12-17 years.
• Subjects:
  Adolescent BNT162 Vaccine Child CoronaVirus Infections COVID-19 COVID-19 Testing Female Humans Male Vaccine Efficacy
• Source:
  MMWR Morbidity Mortal Weekly Rep. 70(5152):1761-1765
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/MMWRmm705152a2
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  34968373
• Pubmed Central ID:
  PMC8736269
• Document Type:
  Journal Article
• Place as Subject:
  Arizona
• Pages in Document:
  5 pdf pages
• Volume:
  70
• Issue:
  51
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:bf29cff92d44d0f88ef2504d645b766b04edf429b2e8349b89b2fc647e387253cfa0005a6b0c45a63b7de2e798ad229fded54b3376137353086a4ab4419248b1
• Download URL:
  https://stacks.cdc.gov/view/cdc/113665/cdc_113665_DS1.pdf
• File Type:
  [PDF - 214.37 KB ]